Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL versus MILI.
CHLORAMPHENICOL vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
50-100 mg/kg/day IV divided every 6 hours (not to exceed 4 g/day); for susceptible severe infections, 12.5-25 mg/kg IV every 6 hours.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
1.5-4.0 hours in adults; prolonged to 3-7 hours in neonates and up to 24 hours in severe hepatic impairment
Clinical Note
moderateChloramphenicol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Ketoconazole
"The metabolism of Ketoconazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Ticlopidine
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
~90% renal (5-10% unchanged; remainder as inactive glucuronide), ~10% biliary/fecal
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category D/X
Category C
Antibiotic
Antibiotic
"The metabolism of Ticlopidine can be decreased when combined with Chloramphenicol."